AI in the Exam Room: GW RhythmX and Microsoft Team Up on Precision Care

PALO ALTO, CA – July 15, 2026 – A new frontier in clinical artificial intelligence is opening up as GW RhythmX announced that its RhythmX Pulse solution is now available on the Microsoft Marketplace. The move integrates the company’s “Precision Care AI” directly with Microsoft’s Dragon Copilot, aiming to transform the standard patient encounter from a data-entry exercise into an opportunity for real-time, hyper-personalized medical guidance.

For clinicians grappling with administrative burdens, the launch promises more than just efficiency. It represents a significant step toward embedding intelligent, data-driven support directly into the care-delivery workflow, helping doctors act on what is said in the exam room, not just document it.

The AI Assistant Steps into the Clinic

At its core, RhythmX Pulse functions as an intelligent layer on top of Microsoft's ambient clinical intelligence. While Dragon Copilot automatically captures and transcribes the patient-clinician conversation, RhythmX Pulse analyzes that dialogue in real time. It cross-references the discussion against a vast repository of patient-specific information, including medical history, current medications, established clinical guidelines, social context, payer rules, and formulary requirements.

The system then surfaces a range of personalized recommendations before the patient even leaves the room. These can include alerts for care gaps, suggestions for documentation improvements, opportunities for more accurate HCC and medical coding, guideline-based treatment options, and formulary-aware medication alternatives. Crucially, clinicians remain in full control, with the ability to accept, edit, or dismiss any AI-generated suggestion.

This approach directly addresses the growing issue of clinician burnout, a significant portion of which is attributed to administrative tasks. Recent industry data indicates that nearly half of clinicians using AI for documentation save over 130 hours annually, with many reporting reduced work-related stress. A pilot program at Presbyterian Healthcare Services (PHS) demonstrated the platform's potential, enabling clinicians to identify and review over 200 conditions across 10,000 patient encounters in just weeks—a task that previously involved hours of manual chart review.

"The next major opportunity is to use the clinical context captured during the encounter to support more personalized decisions at the point of care," said Prasanna Mohanty, EVP & President, Ambulatory Care at Sentara Health. "Integrating Precision Care AI can help bring relevant history, guidelines, and other patient-specific factors into the decision-making process while the patient is still in the room."

Microsoft's Strategic Play in a Crowded AI Market

The integration of RhythmX Pulse into the Microsoft ecosystem is a calculated move within a much larger strategy. For Microsoft, which acquired Dragon's parent company Nuance Communications for approximately $16 billion in 2021, this partnership represents the evolution from AI-powered transcription to AI-driven intelligence. It deepens the value of its Microsoft Cloud for Healthcare platform by adding a specialized, clinically validated layer of decision support.

The Microsoft Marketplace serves as a critical distribution channel, connecting trusted, third-party solutions with its global customer base of health systems. This ecosystem approach allows Microsoft to rapidly expand its capabilities and offer highly specialized tools without developing every solution in-house. For healthcare providers already invested in the Microsoft ecosystem, the new offering is particularly attractive, as existing Dragon Copilot users can add RhythmX Pulse directly from the marketplace with no separate, complex implementation project.

"We're pleased to welcome GWRhythmX to Microsoft Marketplace," said Cyril Belikoff, vice president of Microsoft Azure Product Marketing. "Marketplace connects trusted solutions from global partners with customers worldwide, making it easy to find and deploy apps that work seamlessly with Microsoft products."

Beyond the EMR: A Leap Towards Proactive Healthcare

This development signals a broader shift in health technology, moving beyond the passive, record-keeping function of traditional Electronic Health Records (EHRs) toward proactive, intelligent systems that anticipate clinical needs. GW RhythmX’s focus on "Precision Care AI" is built on this premise, distinguishing itself by unifying data from over eight distinct sources to create a truly holistic patient view.

"Clinical AI is more than summarization or guideline lookups," explained Deepthi Bathina, founder and CEO of GW RhythmX. She emphasized that the goal is to provide a clear "next best action" by checking the encounter against a patient's full history, the latest guidelines, and even social and financial intelligence. This moves beyond generic guidance to offer validated, hyper-personalized recommendations.

However, the path to AI adoption is not without its challenges. Industry studies show that a majority of clinicians harbor concerns about AI inaccuracies, or "hallucinations," and the potential for deskilling. To build trust, GW RhythmX emphasizes its physician-led governance and its platform's "explainable AI agents." The company reports having completed more than 170,000 physician-reviewed clinical validations to ensure every recommendation is backed by evidence and quality assurance.

An Integrated Future for Patient Care

This launch is just the first phase of a broader roadmap between GW RhythmX and Microsoft. Future capabilities are planned to extend these clinically validated recommendations across the entire care journey. This includes pre-visit preparations to equip clinicians with insights beforehand, real-time conversational guidance during appointments, and tools for post-visit care-team coordination and long-term patient management.

The company behind the technology, GW RhythmX, was formed from the merger of Get Well, a leader in patient engagement, and RhythmX AI, a clinical AI specialist. This combination uniquely positions the company to create an integrated stack that connects precision analytics and clinical decision support with patient engagement and workflow optimization. Backed by SymphonyAI Group and its over $1 billion in R&D investment, GW RhythmX draws on longitudinal data spanning 300 million patients to refine its powerful models. Its solutions are deployed across more than 150 health systems, reaching over 85 million patients, including 8 million U.S. military veterans.